Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 175865-59-5] Valganciclovirhydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-A0032A
Brand:	MCE
CAS:	175865-59-5

Overview

MDL	MFCD08460118
Molecular Weight	390.82
Molecular Formula	C14H23ClN6O5
SMILES	N[C@@H](C(C)C)C(OCC(OCN1C=NC2=C1N=C(N)NC2=O)CO)=O.[H]Cl

For research use only. We do not sell to patients.

Summary

Valganciclovir (hydrochloride), the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections. IC50 Value: Target: CMV in vitro: In cell culture model systems using Caco-2 cells for PEPT1 and SKPT cells for PEPT2, valganciclovir inhibited glycylsarcosine transport mediated by PEPT1 and PEPT2 with K(i) values (inhibition constant) of 1.68+/-0.30 and 0.043+/- 0.005 mM, respectively. The inhibition by valganciclovir was competitive in both cases [1]. in vivo: 37 patients were enrolled; 19 patients received treatment with VGV and 18 patients received treatment with GCV. The VGV was not inferior in efficacy to GCV as pre-emptive therapy, with rates of viral clearance at 28 days of 89.5% and 83%, respectively (P-value for non-inferiority = 0.030). Toxicities were similar between the 2 arms. No patients developed CMV disease [2]. Patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily orvalganciclovir 450 mg orally twice daily. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004) [3].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00031434	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections	July 2002	Phase 1\|Phase 2
NCT00017784	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Phase 3
NCT00006145	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections\|HIV Infections	August 2000	Phase 3
NCT00330018	Hadassah Medical Organization	Bone Marrow Transplantation\|Cytomegalovirus	February 2006	Phase 3
NCT00917826	HemaQuest Pharmaceuticals Inc.\|Boston University	EBV Lymphomas\|Lympho-proliferative Diseases	September 2008	Phase 2
NCT00189150	University of Michigan\|Hoffmann-La Roche	Kidney Transplant Recipient\|Heart Transplant Recipient	April 2005	Phase 4
NCT00372229	Hoffmann-La Roche	Cytomegalovirus Infections	May 2006	Phase 3
NCT00090766	Hoffmann-La Roche	Cytomegalovirus Infections	May 2004	Phase 2\|Phase 3
NCT00364052	Oregon Health and Science University	Liver Transplantation	August 2006
NCT00466817	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infection	June 2008	Phase 3
NCT00828503	Marcus Saemann\|Medical University of Vienna	Cytomegalovirus Disease	December 2008	Phase 2
NCT02606266	Assistance Publique - Hôpitaux de Paris	Congenital Cytomegalovirus (CMV)	July 11, 2017	Phase 2\|Phase 3
NCT02927067	Shire\|Takeda Development Center Americas, Inc.\|Takeda	Cytomegalovirus (CMV)	April 14, 2017	Phase 3
NCT00966836	University of Bologna	Heart Transplantation\|Cardiac Allograft Vasculopathy\|Cytomegalovirus Infection	April 2009	Phase 3
NCT01655212	Dr. Ann C.T.M. Vossen\|Stichting Nuts Ohra\|Leiden University Medical Center	Congenital Cytomegalovirus Infection\|Sensorineural Hearing Loss	June 2012	Phase 3
NCT00275314	University of Pittsburgh\|Hoffmann-La Roche	Kidney Transplant	February 2006	Phase 3
NCT03698435	University Medical Center Groningen	Cytomegalovirus Infections	May 25, 2018
NCT00217503	National Cancer Institute (NCI)	Lymphoma	July 2005	Phase 2
NCT03915366	Hospital Universitario 12 de Octubre\|University Hospital, Bordeaux\|Institut National de la Santé Et de la Recherche Médicale, France\|PENTA Foundation\|Centre Hospitalier Cocody\|Malawi-Liverpool-Wellcome Trust Clinical Research Programme\|Eduardo Mondlane University\|Centro de Investigação em Saúde de Manhiça\|Stichting Katholieke Universiteit\|Barcelona Institute for Global Health\|University of Lincoln\|Makerere University\|University Teaching Hospital, Lusaka, Zambia\|University of Zimbabwe	Pneumonia\|HIV+AIDS\|Tuberculosis\|Cytomegalovirus Infections	March 1, 2020	Phase 2\|Phase 3
NCT00264290	University of California, San Francisco\|Roche Pharma AG	HIV Infections\|Cytomegalovirus Infections	August 2006	Phase 4
NCT01165580	Hoffmann-La Roche	Cytomegalovirus Infections, Heart Transplantation	May 2011	Phase 1
NCT00431353	Hoffmann-La Roche	Cytomegalovirus Infections	April 2004	Phase 4
NCT01255644	Medical University of Vienna	Chronic Lymphocytic Leukemia	December 2010	Phase 4
NCT00478465	Stanford University	Chronic Fatigue Syndrome	May 2007	Phase 1\|Phase 2
NCT00992732	HemaQuest Pharmaceuticals Inc.	Lymphoid Malignancies\|Lymphoproliferative Disorders	May 2010	Phase 2
NCT00092222	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoproliferative Disorder\|HHV-8\|Malignancy\|HIV	October 28, 2004	Phase 2
NCT02439957	Chimerix	Cytomegalovirus Disease\|Kidney Transplant Infection	September 2015	Phase 3
NCT00002222	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT05041426	Fernanda P Silveira, MD, MS\|Merck Sharp & Dohme LLC\|University of Pittsburgh	Lung Transplant\|CMV	December 6, 2021	Phase 2
NCT00002377	Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections	January 1997	Phase 3
NCT00227370	Scott Palmer\|Roche Pharma AG\|Duke University	Cytomegalovirus Infections	July 2003	Phase 3
NCT00237653	University Hospital, Grenoble	Cytomegalovirus Infections\|Inflammatory Bowel Diseases	February 2004	Phase 3
NCT03699254	Maimónides Biomedical Research Institute of Córdoba\|Instituto de Salud Carlos III	Transplantation Infection\|Cytomegalovirus Infections	April 5, 2019	Phase 3
NCT01552369	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infection	October 29, 2012	Phase 4
NCT00275665	Mayo Clinic\|Roche Pharma AG\|Fred Hutchinson Cancer Center\|City of Hope National Medical Center\|University of Florida\|University of Michigan	Bone Marrow Stem Cell Transplant	November 2001	Phase 3
NCT02761291	Chang Gung Memorial Hospital\|TTY Biopharm	Nasopharyngeal Carcinoma	May 2016	Phase 1
NCT03631316	Luis Eduardo Morales Buenrostro\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Kidney Transplantation\|Cytomegalovirus Infections\|Pharmacokinetics\|Therapeutic Equivalency	March 1, 2018	Not Applicable
NCT00141037	National Institute of Allergy and Infectious Diseases (NIAID)\|Astellas Pharma Inc\|Hoffmann-La Roche	Kidney Diseases\|Kidney Transplantation\|Kidney Transplant\|Renal Transplantation\|Renal Transplant	March 2004	Phase 1\|Phase 2
NCT03107871	Albert Park\|National Institute on Deafness and Other Communication Disorders (NIDCD)\|Genentech, Inc.\|University of Utah	Cmv Congenital\|CMV\|Congenital Cmv\|SNHL\|Sensorineural Hearing Loss	August 31, 2018	Phase 2
NCT02871401	Vanderbilt University Medical Center\|Genentech, Inc.	Idiopathic Pulmonary Fibrosis	January 3, 2018	Phase 1
NCT00294515	Hoffmann-La Roche	Cytomegalovirus Infections	March 31, 2006	Phase 3
NCT01376804	Hoffmann-La Roche	Kidney Transplantation, Cytomegalovirus Infections	July 31, 2011	Phase 4
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT01509404	Medical University of South Carolina\|CSL Behring	Cytomegalovirus Disease	November 2011	Phase 4
NCT02297854	Dr. Reddy´s Laboratories Limited	Healthy	July 2011	Phase 1
NCT04116411	Cecilia Soderberg-Naucler\|Karolinska University Hospital\|Karolinska Institutet	Glioblastoma Multiforme	September 4, 2019	Phase 2
NCT03301415	National Institute of Allergy and Infectious Diseases (NIAID)	Congenital Cytomegalovirus Infection	April 2, 2019	Phase 2
NCT03443869	Merck Sharp & Dohme LLC	CMV Disease	May 3, 2018	Phase 3
NCT03586284	University of California, San Francisco\|Huang Pacific Foundation\|Khon Kaen University\|King Chulalongkorn Memorial Hospital	Cytomegalovirus Anterior Uveitis	March 15, 2020	Phase 2\|Phase 3
NCT00386412	PETHEMA Foundation	Cytomegalovirus Infection	November 2005	Phase 2
NCT00562770	M.D. Anderson Cancer Center\|Roche Pharma AG	Chronic Lymphocytic Leukemia\|Leukemia	September 2003	Phase 2
NCT05011058	Viracta Therapeutics, Inc.	Epstein-Barr Virus Associated Lymphoproliferative Disorder\|EBV-Related PTLD\|EBV Related Non-Hodgkin´s Lymphoma\|Extranodal NK+T-cell Lymphoma\|EBV-Positive DLBCL, Nos\|EBV Associated Lymphoma\|EBV-Related Hodgkin Lymphoma\|EBV Related PTCL, Nos	May 28, 2021	Phase 2
NCT01199562	City of Hope Medical Center\|National Cancer Institute (NCI)	Hematopoietic+Lymphoid Cancer\|Accelerated Phase Chronic Myelogenous Leukemia\|Acute Undifferentiated Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Aplastic Anemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Cytomegalovirus Infection\|de Novo Myelodysplastic Syndromes\|Essential Thrombocythemia\|Extramedullary Plasmacytoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Isolated Plasmacytoma of Bone\|Mast Cell Leukemia\|Meningeal Chronic Myelogenous Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Polycythemia Vera\|Post-transplant Lymphoproliferative Disorder\|Previously Treated Myelodysplastic Syndromes\|Primary Myelofibrosis\|Primary Systemic Amyloidosis\|Progressive Hairy Cell Leukemia, Initial Treatment\|Prolymphocytic Leukemia\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Secondary Myelofibrosis\|Splenic Marginal Zone Lymphoma\|Stage 0 Chronic Lymphocytic Leukemia\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Adult T-cell Leukemia+Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Multiple Myeloma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Adult T-cell Leukemia+Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Multiple Myeloma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia+Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Multiple Myeloma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia+Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Waldenstrom Macroglobulinemia	December 2010
NCT00016068	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Infection	January 2001	Phase 3
NCT01329185	University of Minnesota	EBV Viremia\|CMV Viremia	June 2011	Phase 2
NCT02973464	First Affiliated Hospital Xi´an Jiaotong University	Renal Transplant Recipients	June 2016
NCT03397706	Viracta Therapeutics, Inc.	Epstein-Barr Virus Associated Lymphoma\|Lymphoproliferative Disorders	March 29, 2018	Phase 1\|Phase 2
NCT02931539	Shire\|Takeda	Cytomegalovirus (CMV)	December 22, 2016	Phase 3
NCT01649869	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infection	February 24, 2015	Phase 2
NCT01663740	Hoffmann-La Roche	Cytomegalovirus Infections	January 30, 2012	Phase 4
NCT02005822	Dr. Ann C.T.M. Vossen\|Stichting Nuts Ohra\|Leiden University Medical Center	Congenital Cytomegalovirus Infection\|Sensorineural Hearing Loss	October 22, 2013	Phase 3
NCT00377741	Hoffmann-La Roche	Cytomegalovirus Infections	December 2004	Phase 1
NCT04724447	Laureate Institute for Brain Research, Inc.	Major Depressive Disorder	November 23, 2021	Phase 1\|Phase 2
NCT00387530	University of California, San Diego\|National Cancer Institute (NCI)	Gastric Cancer\|Head and Neck Cancer\|Lymphoma\|Lymphoproliferative Disorder	May 2006	Phase 2
NCT04064697	Centre Hospitalier Universitaire de Saint Etienne\|Ministry of Health, France	Ulcerative Colitis, Unspecified	April 22, 2021	Phase 3
NCT00034385	National Institutes of Health Clinical Center (CC)	Kidney Trasplant	April 24, 2002	Phase 4
NCT01185223	Pierrel Research Europe GmbH\|Roche Pharma AG	Allogeneic Stem Cell Transplantation	September 2010	Phase 3
NCT03296553	National Institute of Cancerología\|Instituto Nacional de Enfermedades Respiratorias	Kaposi Sarcoma\|Human Immunodeficiency Virus\|Immune Reconstitution Syndrome	October 1, 2015	Phase 2
NCT01049633	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Type 1 Diabetes Mellitus
NCT01441063	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Castleman Disease\|Multicentric Castleman Disease\|Giant Lymph Node Hyperplasia	September 13, 2011	Phase 2
NCT00400322	Karolinska Institutet\|Karolinska University Hospital	Glioblastoma Multiforme\|Cytomegalovirus Infection	August 2006	Not Applicable
NCT02503982	Rabin Medical Center	Infection in Solid Organ Transplant Recipients	December 2014	Phase 4
NCT00194467	University of Washington\|Hoffmann-La Roche	Human Herpesvirus 8	December 2002	Phase 2
NCT01972035	University of Minnesota	Transplantation Infection\|Epstein-Barr Virus Infections\|Cytomegalovirus Infections	August 1, 2014	Phase 2
NCT01446445	Nuria Lloberas\|Ministerio de Sanidad, Servicios Sociales e Igualdad\|Hospital Universitari de Bellvitge	Infection in Solid Organ Transplant Recipients	December 2011	Phase 4
NCT00374686	Washington University School of Medicine\|Hoffmann-La Roche	Cytomegalovirus Infection	March 2003	Not Applicable
NCT00241345	Washington University School of Medicine	Cytomegalovirus Infections	June 2004	Phase 3
NCT05166577	Viracta Therapeutics, Inc.	Nasopharyngeal Carcinoma\|EBV-Related Gastric Carcinoma\|EBV-Related Leiomyosarcoma\|EBV Related Carcinoma\|EBV-Related Sarcoma	October 7, 2021	Phase 1\|Phase 2
NCT05238220	Piedmont Healthcare\|ViraCor Laboratories	Kidney Transplant; Complications	January 4, 2021
NCT00361933	University of Washington\|Hoffmann-La Roche	Giant Lymph Node Hyperplasia	December 2008	Phase 4
NCT02439970	Chimerix	Cytomegalovirus Disease	September 2015	Phase 3
NCT02370758	University Health Network, Toronto	Cytomegalovirus Viraemia	November 2014	Not Applicable
NCT02296723	Dr. Reddy´s Laboratories Limited	Healthy	July 2011	Phase 1
NCT00096538	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|New York Presbyterian Hospital\|Weill Medical College of Cornell University\|University of North Carolina, Chapel Hill	Sarcoma	April 2004	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 127.94 mM ; Need ultrasonic)

H ₂ O : ≥ 50 mg/mL ( 127.94 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5587 mL	12.7936 mL	25.5872 mL
5 mM	0.5117 mL	2.5587 mL	5.1174 mL
10 mM	0.2559 mL	1.2794 mL	2.5587 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (255.87 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
[2] Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67.
[3] O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15;111(4):1816-9.

Synonyms

L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, hydrochloride (1:1)

L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, monohydrochloride

RS 079070-194

Valganciclovir hydrochloride

Ro 107-9070/194

Valcyte

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart